Kestrel Investment Management’s Haemonetics HAE Stock Holding History

Kestrel Investment Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.49M	Sell	97,400 -700	-0.7%	-$45.6K	3.28%	9
2025 Q4	$7.86M	Sell	98,100 -3,700	-4%	-$249K	4.46%	4
2025 Q3	$4.96M	Buy	+101,800	New	+$6.3M	2.8%	14
2016 Q2	–	Sell	-169,300	Closed	-$5.92M	–	43
2016 Q1	$5.92M	Sell	169,300 -2,700	-2%	-$87.2K	2.28%	18
2015 Q4	$5.54M	Sell	172,000 -26,150	-13%	-$848K	2.22%	23
2015 Q3	$6.4M	Sell	198,150 -2,500	-1%	-$94.1K	2.23%	22
2015 Q2	$8.3M	Sell	200,650 -197,000	-50%	-$8.3M	2.56%	19
2015 Q1	$17.9M	Sell	397,650 -12,000	-3%	-$502K	2.44%	18
2014 Q4	$15.3M	Sell	409,650 -8,900	-2%	-$326K	2.04%	20
2014 Q3	$14.6M	Sell	418,550 -14,500	-3%	-$517K	2.07%	17
2014 Q2	$15.3M	Sell	433,050 -8,200	-2%	-$274K	1.9%	22
2014 Q1	$14.4M	Sell	441,250 -11,150	-2%	-$426K	1.78%	23
2013 Q4	$19.1M	Sell	452,400 -96,800	-18%	-$3.98M	2.34%	17
2013 Q3	$21.9M	Sell	549,200 -10,100	-2%	-$424K	2.25%	19
2013 Q2	$23.1M	Buy	+559,300	New	+$22.6M	2.56%	14

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kestrel Investment Management's HAE Position: Q1 2026 in Review

Kestrel Investment Management reduced its Haemonetics (HAE) stake by 0.71% in Q1 2026, selling an estimated $45.6K and leaving 97,400 shares worth $5.49M. The position accounts for 3.28% of the portfolio, ranked #9.

Kestrel Investment Management first reported a position in HAE in Q2 2013 and has held it in 15 quarters since. The position peaked at $23.1M in Q2 2013. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Kestrel Investment Management held 97,400 shares of Haemonetics worth $5.49M as of Q1 2026.
Kestrel Investment Management sold 700 Haemonetics shares in Q1 2026, an estimated $45.6K.
Haemonetics made up 3.28% of Kestrel Investment Management's portfolio in Q1 2026, its #9 holding.
Kestrel Investment Management first reported a position in Haemonetics in Q2 2013 and has held it in 15 quarters since.
Kestrel Investment Management's Haemonetics position peaked at $23.1M in Q2 2013.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Kestrel Investment Management's 13F filing for Q1 2026, filed 5 May 2026.